Title 25, PROFESSIONS AND OCCUPATIONS

Sec. 12.5. "Prescription drug monitoring program data", for purposes of section 19 of this chapter, means the following: (1) Information received under section 17 of this chapter, including clinical or required alerts as defined by the board. (2) Any other information determined …

Sec. 13. As used in this chapter, "pseudoephedrine" includes only pseudoephedrine that is dispensed pursuant to a prescription or drug order. As added by P.L.51-2019, SEC.8.

Sec. 14. As used in this chapter, "recipient" means an individual for whom a controlled substance is dispensed. As added by P.L.51-2019, SEC.8.

Sec. 15. As used in this chapter, "recipient representative" means the individual to whom a controlled substance is dispensed if the recipient is either less than eighteen (18) years of age or unavailable to receive the controlled substance. As added by P.L.51-2019, SEC.8.

Sec. 16. As used in this chapter, "state" means any state of the United States or the District of Columbia. As added by P.L.51-2019, SEC.8.

Sec. 17. (a) Except as provided in section 17.5 of this chapter, the board shall provide for an ephedrine, pseudoephedrine, and controlled substance prescription monitoring program that includes the following components: (1) Each time ephedrine, pseudoephedrine, or a controlled s…

Sec. 17.5. A dispenser is not required to transmit information required under section 17 of this chapter to the INSPECT program in the following circumstances: (1) A drug is administered directly to a patient. (2) A drug is dispensed by a veterinary practitioner, if the quantity …

Sec. 18. (a) The INSPECT program must do the following: (1) Create a data base for information required to be transmitted under section 17 of this chapter in the form required under rules adopted by the board, including search capability for the following: (A) An ephedrine, pseud…

Sec. 18.5. Before reporting patient information to the INSPECT program, an opioid treatment program shall comply with 42 CFR 2.36 and 42 CFR 2.31 in obtaining patient consent. As added by P.L.133-2026, SEC.5.

Sec. 19. (a) Information received by the INSPECT program under section 17 of this chapter is confidential. (b) The board shall carry out a program to protect the confidentiality of the information described in subsection (a). The board may disclose the information to another pers…

Sec. 19.5. A practitioner who is a veterinarian and who is treating an animal may obtain information about: (1) the owner of the animal; or (2) the individual to whom an opioid or benzodiazepine will be dispensed for the animal; from the data base before prescribing an opioid or …

Sec. 2. As used in this chapter, "committee" refers to the INSPECT oversight committee established by section 24 of this chapter. As added by P.L.51-2019, SEC.8.

Sec. 2.5. As used in this chapter, "controlled substance" has the meaning set forth in IC 35-48-1.1-7. The term includes gabapentin. As added by P.L.246-2019, SEC.21 and P.L.264-2019, SEC.10. Amended by P.L.186-2025, SEC.142.

Sec. 20. A practitioner who is permitted to distribute, dispense, prescribe, conduct research with respect to, or administer ephedrine, pseudoephedrine, or a controlled substance in the course of the practitioner's professional practice or research in the United States must be ce…

Sec. 21. (a) Each board described in IC 25-0.5-11-1 that regulates a health care provider that prescribes or dispenses prescription drugs may review and act upon the unsolicited dissemination of exception reports under section 19 of this chapter. (b) Upon receipt of an exception …

Sec. 22. (a) The board shall adopt rules under IC 4-22-2 to implement this chapter, including the following: (1) Information collection and retrieval procedures for the INSPECT program, including the controlled substances to be included in the program required under section 17 of…

Sec. 23. (a) The controlled substances data fund is established to fund the administration of the INSPECT program. The fund shall be administered by the Indiana professional licensing agency. (b) Expenses of administering the fund shall be paid from money in the fund. The fund co…

Sec. 24. (a) The INSPECT oversight committee is established. (b) The committee consists of the following members: (1) The president of the board or the president's designee, who shall serve as the chairperson of the committee. (2) The commissioner of the Indiana department of hea…

Sec. 25. A person who knowingly or intentionally releases confidential information in an unauthorized manner violates this chapter and commits a Class A misdemeanor. As added by P.L.51-2019, SEC.8.

Sec. 26. Any administrative rule adopted under IC 35-48-7-12.1 (before its repeal) is hereby considered to be adopted under section 22 of this chapter. As added by P.L.246-2019, SEC.22 and P.L.264-2019, SEC.11.

Sec. 3. As used in this chapter, "dispense" means to deliver a controlled substance to an ultimate user or research subject by or pursuant to the lawful order of a practitioner and includes the prescribing, administering, packaging, labeling, or compounding necessary to prepare t…

Sec. 4. As used in this chapter, "ephedrine" includes only ephedrine that is dispensed pursuant to a prescription or drug order. As added by P.L.51-2019, SEC.8.

Sec. 5. As used in this chapter, "exception report" means a record of data concerning: (1) a practitioner practicing a particular specialty or field of health care; (2) a dispenser doing business in a particular location; or (3) a recipient; that indicates dispensing or receiving…

Sec. 6. As used in this chapter, "identification number" refers to the following: (1) The unique number contained on any of the following: (A) A valid driver's license of a recipient or a recipient's representative issued under Indiana law or the law of any other state. (B) A rec…

Sec. 7. As used in this chapter, "INSPECT" means the Indiana scheduled prescription electronic collection and tracking program established by IC 25-1-13-4. As added by P.L.51-2019, SEC.8.

Sec. 8. As used in this chapter, "interoperability" refers to the INSPECT program electronically sharing reported information with another state concerning the dispensing of a controlled substance: (1) to a recipient who resides in the other state; or (2) prescribed by a practiti…

Sec. 9. (a) As used in this chapter, "pain management clinic" means a publicly or privately owned facility that primarily engages in the treatment of pain or pain management through prescribing controlled substances. (b) The term does not include the following: (1) A hospital lic…